Skip to main content

Autolus Therapeutics plc

AUTL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001730463

In the last 90 days, Autolus Therapeutics plc insiders filed 0 open-market purchases and 1 sale; 83 institutions reported holding it in 13F filings for Q2 2026, worth $212.0M in total; no superinvestor holds it.

Q1 2025 vs. Q4 2024

How the institutions holding Autolus Therapeutics plc changed between Q4 2024 and Q1 2025.

All holders in Q1 2025All holders in Q4 2024

13F holders of AUTL: Q4 2024 compared with Q1 2025
MeasureQ4 2024Q1 2025Change
Holders11095−15
Shares168.4M168.1M−353.5K (−0.2%)
Value$395.4M$261.0M−$134.4M (−34.0%)

New holders (8)

Institutions that held Autolus Therapeutics plc at the end of Q1 2025 but not at the end of Q4 2024.

Institutions new to AUTL in Q1 2025
InstitutionSharesValue% of portfolio
Knott David M Jr420,000$651.0K0.31%
Edentree Asset Management Ltd300,000$462.0K0.16%
Vident Advisory, LLC155,504$241.0K0.00%
NEOS Investment Management LLC110,428$171.2K0.00%
Tema ETFs LLC110,428$171.2K0.05%
Virtus Investment Advisers, Inc.61,027$94.6K0.03%
JustInvest LLC18,611$28.8K0.00%
EverSource Wealth Advisors, LLC6,112$9.47K0.00%

Sold out (23)

Institutions that held Autolus Therapeutics plc at the end of Q4 2024 and filed for Q1 2025 without it.